5AM Venture Management LLC Purchases Shares of 2,353,304 Artiva Biotherapeutics, Inc. $ARTV

5AM Venture Management LLC purchased a new stake in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 2,353,304 shares of the company's stock, valued at approximately $22,827,049. Artiva Biotherapeutics accounts for 0.0% of 5AM Venture Management LLC's holdings, making the stock its 6th largest position. 5AM Venture Management LLC owned about 4.81% of Artiva Biotherapeutics at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in ARTV. Blue Owl Capital Holdings LP purchased a new stake in Artiva Biotherapeutics during the second quarter valued at about $8,483,000. BlackRock Inc. purchased a new stake in Artiva Biotherapeutics during the second quarter valued at about $6,739,000. Citadel Advisors LLC boosted its position in Artiva Biotherapeutics by 419.3% during the third quarter. Citadel Advisors LLC now owns 798,397 shares of the company's stock valued at $2,291,000 after buying an additional 644,658 shares during the period. ADAR1 Capital Management LLC purchased a new stake in Artiva Biotherapeutics during the second quarter valued at about $1,151,000. Finally, BNP Paribas Financial Markets boosted its position in Artiva Biotherapeutics by 14,463.5% during the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company's stock valued at $340,000 after buying an additional 117,733 shares during the period.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on ARTV shares. HC Wainwright increased their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a "buy" rating in a report on Friday, May 8th. Wall Street Zen upgraded shares of Artiva Biotherapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Artiva Biotherapeutics in a report on Tuesday, July 21st. Cantor Fitzgerald reiterated an "overweight" rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $41.00 target price on shares of Artiva Biotherapeutics in a report on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, Artiva Biotherapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $39.00.

Insider Activity at Artiva Biotherapeutics

In other news, Director Ra Capital Management, L.P. acquired 24,944 shares of the firm's stock in a transaction dated Friday, July 31st. The shares were purchased at an average cost of $9.93 per share, for a total transaction of $247,693.92. Following the transaction, the director directly owned 17,329,570 shares of the company's stock, valued at approximately $172,082,630.10. This trade represents a 0.14% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last 90 days, insiders have acquired 1,965,251 shares of company stock worth $16,188,035. 1.80% of the stock is owned by company insiders.

Artiva Biotherapeutics Trading Down 7.1%

Shares of ARTV stock opened at $11.09 on Friday. The firm's 50 day moving average is $10.38 and its 200 day moving average is $8.49. The stock has a market capitalization of $542.19 million, a P/E ratio of -3.36 and a beta of 2.16. Artiva Biotherapeutics, Inc. has a 12-month low of $2.22 and a 12-month high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share for the quarter, hitting the consensus estimate of ($0.63). As a group, equities analysts predict that Artiva Biotherapeutics, Inc. will post -2.62 earnings per share for the current year.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company's proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva's pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source